Even though our data are unable to distinguish between CD4+ and CD8+ TCRs, they strongly support the hypothesis that tumor MHC class II neoantigens may be important in coordinating tumor-specific B and T cell responses, as the tumor MHC class II neoantigen landscape correlated with both B and T clonal structures. This evidence concerns the gene CD8A and neoplasm.